Insulet Slides After Q1 Beat as Omnipod 5 Class I Recall Overhang Persists
Insulet shares fell as investors digested first-quarter 2026 results released May 6, 2026, despite an earnings and revenue beat. The decline is being amplified by ongoing scrutiny of a Class I recall involving certain Omnipod 5 pod lots tied to potential insulin under-delivery risk.
1) What’s moving the stock
Insulet (PODD) is down about 3.66% on Wednesday, May 6, 2026, following the company’s first-quarter 2026 results and investor call. The move comes even as quarterly results topped consensus expectations, signaling that near-term positioning and risk concerns are outweighing the headline beat. (investor.insulet.com)
2) Earnings beat, but the tape stays heavy
In the first quarter, Insulet reported revenue of $761.7 million and diluted EPS of $1.42, both ahead of published expectations in the market. The stock reaction suggests investors are focusing less on the quarter’s upside and more on forward risk factors and sentiment after an extended drawdown toward recent lows. (investing.com)
3) Recall overhang remains in focus
A key overhang is the FDA’s Class I recall communication for certain Omnipod 5 Pods, citing a risk that a small tear in internal insulin-delivery tubing could cause insulin to leak inside the pod and potentially lead to under-delivery. The FDA communication notes Insulet reported 29 serious injuries and no deaths as of April 17, 2026, and the FDA updated its public notice on April 29–30, 2026. (fda.gov)
4) What to watch next
Investors will watch for any changes in demand trends, replacement cadence and potential cost impacts tied to recall-related actions, alongside updates on product integrations and launches referenced around the earnings release and call. Additional regulatory or customer-communication updates on impacted Omnipod 5 lots could also shift sentiment quickly. (fda.gov)